Lars Bullinger

42.7k total citations · 8 hit papers
321 papers, 16.6k citations indexed

About

Lars Bullinger is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Lars Bullinger has authored 321 papers receiving a total of 16.6k indexed citations (citations by other indexed papers that have themselves been cited), including 191 papers in Hematology, 175 papers in Molecular Biology and 81 papers in Genetics. Recurrent topics in Lars Bullinger's work include Acute Myeloid Leukemia Research (160 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (42 papers) and Chronic Myeloid Leukemia Treatments (38 papers). Lars Bullinger is often cited by papers focused on Acute Myeloid Leukemia Research (160 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (42 papers) and Chronic Myeloid Leukemia Treatments (38 papers). Lars Bullinger collaborates with scholars based in Germany, United States and United Kingdom. Lars Bullinger's co-authors include Hartmut Döhner, Konstanze Döhner, Stephan Stilgenbauer, Axel Benner, Richard F. Schlenk, Peter Lichter, Alexander Kröber, Stefan Fröhling, Martin Bentz and Elke Leupolt and has published in prestigious journals such as Science, New England Journal of Medicine and Cell.

In The Last Decade

Lars Bullinger

302 papers receiving 16.4k citations

Hit Papers

Genomic Aberrations and Survival in Chronic Lymphocytic L... 2000 2026 2008 2017 2000 2008 2004 2011 2005 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia
    2000 2.3k citations Hartmut Döhner, Axel Benner et al. profile →
  2. Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia
    2008 1.1k citations Richard F. Schlenk, Konstanze Döhner et al. profile →
  3. Use of Gene-Expression Profiling to Identify Prognostic Subclasses in Adult Acute Myeloid Leukemia
    2004 703 citations Lars Bullinger, Konstanze Döhner et al. profile →
  4. MLL-Rearranged Leukemia Is Dependent on Aberrant H3K79 Methylation by DOT1L
    2011 642 citations Andrei V. Krivtsov, Lars Bullinger et al. profile →
  5. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations
    2005 603 citations Konstanze Döhner, Richard F. Schlenk et al. Blood profile →
  6. V H mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia
    2002 597 citations Axel Benner, Lars Bullinger et al. Blood profile →
  7. IDH1andIDH2Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia WithNPM1Mutation WithoutFLT3Internal Tandem Duplication
    2010 578 citations Richard F. Schlenk, Jan Krönke et al. Journal of Clinical Oncology profile →
  8. Genomics of Acute Myeloid Leukemia Diagnosis and Pathways
    2017 331 citations Lars Bullinger, Konstanze Döhner et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lars Bullinger Germany 57 8.6k 7.7k 5.8k 3.3k 3.0k 321 16.6k
Konstanze Döhner Germany 63 8.4k 1.0× 10.4k 1.4× 5.9k 1.0× 2.3k 0.7× 2.2k 0.7× 272 16.6k
Jonathan E. Kolitz United States 61 5.2k 0.6× 6.6k 0.9× 6.7k 1.2× 4.0k 1.2× 3.7k 1.2× 256 14.4k
Omar Abdel‐Wahab United States 68 10.9k 1.3× 7.4k 1.0× 5.3k 0.9× 1.4k 0.4× 1.9k 0.6× 306 18.6k
Torsten Haferlach Germany 76 9.6k 1.1× 16.5k 2.2× 7.5k 1.3× 2.4k 0.7× 2.8k 0.9× 774 23.4k
Claude Preudhomme France 62 5.7k 0.7× 9.4k 1.2× 4.4k 0.8× 1.3k 0.4× 1.3k 0.4× 356 13.3k
D. Gary Gilliland United States 76 12.2k 1.4× 12.2k 1.6× 9.6k 1.7× 1.1k 0.3× 2.6k 0.9× 144 22.5k
D. Gary Gilliland United States 62 8.4k 1.0× 8.1k 1.1× 4.2k 0.7× 833 0.3× 2.1k 0.7× 126 16.2k
Alessandra Ferrajoli United States 69 4.1k 0.5× 7.4k 1.0× 9.3k 1.6× 6.1k 1.9× 3.6k 1.2× 527 16.4k
David Oscier United Kingdom 67 5.5k 0.6× 7.7k 1.0× 12.1k 2.1× 7.3k 2.2× 5.4k 1.8× 235 19.2k
Rajyalakshmi Luthra United States 65 5.0k 0.6× 4.1k 0.5× 3.6k 0.6× 3.3k 1.0× 826 0.3× 308 13.7k

Countries citing papers authored by Lars Bullinger

Since Specialization
Citations

This map shows the geographic impact of Lars Bullinger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lars Bullinger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lars Bullinger more than expected).

Fields of papers citing papers by Lars Bullinger

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lars Bullinger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lars Bullinger. The network helps show where Lars Bullinger may publish in the future.

Co-authorship network of co-authors of Lars Bullinger

This figure shows the co-authorship network connecting the top 25 collaborators of Lars Bullinger. A scholar is included among the top collaborators of Lars Bullinger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lars Bullinger. Lars Bullinger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mertlitz, Sarah, Katarina Riesner, Mina Jamali, et al.. (2025). Leucine-rich α-2 glycoprotein 1 (LRG1) during inflammatory complications after allogeneic stem cell transplantation and CAR-T cell therapy. Journal for ImmunoTherapy of Cancer. 13(3). e009372–e009372. 1 indexed citations
2.
Liu, Shuang, et al.. (2025). BEscreen: a versatile toolkit to design base editing libraries. Nucleic Acids Research. 53(W1). W68–W72.
3.
Wittenbecher, Friedrich, Jörg Westermann, Peter Thuss‐Patience, et al.. (2024). Effective symptom relief through continuous integration of palliative care in advanced renal cell carcinoma patients: comprehensive measurement using the palliative care base assessment. Palliative Care and Social Practice. 18. 396558216–396558216.
4.
Anker, Markus S., Muhammad Shahzeb Khan, Jan Porthun, et al.. (2024). New Cardiovascular Biomarkers in Patients with Advanced Cancer – A Prospective Study Comparing MR-proADM, MR-proANP, Copeptin, High-Sensitivity Troponin T and NT-proBNP. European Journal of Heart Failure. 27(6). 1047–1055. 2 indexed citations
5.
Jahn, Nikolaus, Maral Saadati, Pierre Fenaux, et al.. (2023). Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients. Leukemia. 37(11). 2187–2196. 22 indexed citations
6.
Ng, Yuen Lam Dora, Evelyn Ramberger, Stephan Bohl, et al.. (2022). Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma. Nature Communications. 13(1). 1009–1009. 42 indexed citations
7.
8.
Greiner, Jochen, Lars Bullinger, Robert K. Hills, et al.. (2021). Survivin’ Acute Myeloid Leukaemia—A Personalised Target for inv(16) Patients. International Journal of Molecular Sciences. 22(19). 10482–10482. 7 indexed citations
9.
Uckelmann, Hannah J., Eric Wong, Charlie Hatton, et al.. (2020). Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia. Science. 367(6477). 586–590. 152 indexed citations
10.
11.
Bullinger, Lars, Konstanze Döhner, & Hartmut Döhner. (2017). Genomics of Acute Myeloid Leukemia Diagnosis and Pathways. Journal of Clinical Oncology. 35(9). 934–946. 331 indexed citations breakdown →
12.
Hess, Moritz, Stefan Lenz, Tamara J. Blätte, Lars Bullinger, & Harald Binder. (2017). Partitioned learning of deep Boltzmann machines for SNP data. Bioinformatics. 33(20). 3173–3180. 23 indexed citations
13.
Giaimo, Benedetto Daniele, Peggy Schwarz, Karin Soller, et al.. (2017). Heterodimerization of AML1/ETO with CBFβ is required for leukemogenesis but not for myeloproliferation. Leukemia. 31(11). 2491–2502. 20 indexed citations
14.
Hieke, Stefanie, et al.. (2016). Integrating multiple molecular sources into a clinical risk prediction signature by extracting complementary information. BMC Bioinformatics. 17(1). 327–327. 8 indexed citations
15.
Bullinger, Lars, Richard F. Schlenk, Marlies Götz, et al.. (2013). PRAME-Induced Inhibition of Retinoic Acid Receptor Signaling-Mediated Differentiation—A Possible Target for ATRA Response in AML without t(15;17). Clinical Cancer Research. 19(9). 2562–2571. 31 indexed citations
16.
Vliet, Martin H. van, Erik Simons, Lars Bullinger, et al.. (2013). Detection of Mutant NPM1 mRNA in Acute Myeloid Leukemia Using Custom Gene Expression Arrays. Genetic Testing and Molecular Biomarkers. 17(4). 295–300. 4 indexed citations
17.
Kvinlaug, Brynn T., Lars Bullinger, Mukundhan Ramaswami, et al.. (2011). Common and Overlapping Oncogenic Pathways Contribute to the Evolution of Acute Myeloid Leukemias. Cancer Research. 71(12). 4117–4129. 37 indexed citations
18.
Sykes, Stephen M., Lars Bullinger, Rukh Yusuf, et al.. (2011). Akt/foxo signaling pathway enforces the differentiation blockade in myeloid leukemias. Experimental Hematology. 39(8). 1 indexed citations
19.
20.
Kharas, Michael G., Christopher J. Lengner, Fátima Al‐Shahrour, et al.. (2010). Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia. DSpace@MIT (Massachusetts Institute of Technology). 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Konstanze Döhner Breakdown of academic impact, for papers by Jonathan E. Kolitz Breakdown of academic impact, for papers by Omar Abdel‐Wahab Breakdown of academic impact, for papers by Torsten Haferlach Breakdown of academic impact, for papers by Claude Preudhomme Breakdown of academic impact, for papers by D. Gary Gilliland Breakdown of academic impact, for papers by D. Gary Gilliland Breakdown of academic impact, for papers by Alessandra Ferrajoli Breakdown of academic impact, for papers by David Oscier Breakdown of academic impact, for papers by Rajyalakshmi Luthra
Rankless by CCL
2026